HPV screening: Available data and recommendations for clinical practice

Current Cancer Therapy Reviews

Volumn 6, Issue 2, 2010, Pages 104-109

  Ronco, Guglielmo ^a   Meijer, Chris J L M ^b  

^a Centre for Cancer Prevention   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Human papillomavirus; Screening

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ACCURACY; AGE DISTRIBUTION; ARTICLE; CANCER PREVENTION; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COLPOSCOPY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DYSKARYOSIS; EARLY DIAGNOSIS; FOLLOW UP; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; LONGITUDINAL STUDY; PRECANCER; PREDICTION; PRIORITY JOURNAL; REPEAT PROCEDURE; SELF CARE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS LOAD; WART VIRUS;

EID: 77952905539     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791202556     Document Type: Article

References (30)

1. McCredie MR, Sharples KI, Paul C, et al. Natural history of cervical neoplasia and risk of invasive caner in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9: 425-34.
2. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007: 26: 441-6.
3. Dalla Palma P, Giorgi Rossi P, Collina G, et al. The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicentre randomized study. Am J Clin Pathol 2009; 132: 125-32.
4. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia grade 2. Obstet Gynecol 2009; 113: 18-25.
5. Cuzick J, Clavel C, Petry C-H, et al. Overview of the European and north American studies on HPV testing in primary cervical screening. Int J Cancer 2006; 119: 1095-101.
6. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolau tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
7. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J.Natl Cancer Inst 2009; 101: 88-99.
8. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papilllomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
9. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672-82.
10. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human Papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
11. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55.
12. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomised controlled trial comparing human papillomavirus testing alone with conventional cytology as a primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
13. Leinonen M, Nieminen P, Kotaniemi Talonen L, et al. Age specific Evaluation of primary human papillomavirus screening vs. conventional cytology in a randomised setting. J Natl Cancer Inst 2009; 101: 1612-32.
14. Kyrgiou M, Koliopulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2003; 370: 1740-2.
15. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337: a1284; doi:10.1136/bmj.a1284.
16. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
17. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a a randomised controlled trial. Lancet Oncol 2010; doi:10.1016/S1470-2045(09)70360-2.
18. Ronco G, Segnan N. Human papillomavirus testing for primary cervical cancer screening. Lancet 2007; 370: 1740-2
19. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-20.
20. Castle PE, Rodríguez AC, Burk RD, et al. Proyecto Epidemiológico Guanacaste (PEG) Group. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009; 339: b2569. doi: 10.1136/bmj.b2569
21. Snijders PJ, Hogewoning CJ, Hesselink AT, et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006; 119: 1102-7.
22. Hesselink AT, Berkhof J, Heideman DA, et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 2009; 124: 381-6.
23. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2008; 9: 937-45.
24. Szarewski A, Ambroisine L, Cadman L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-42.
25. Dokter J, Schroder A, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009; 51: 555-61.
26. Bhatla N, Dar L, Patro AR, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physiciancollected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol 2009; 33: 446-50.
27. Sanner K, Wikström I, Strand A, Lindell M, Wilander E. Selfsampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009; 101: 871-4.
28. De Alba I, Anton-Culver H, Hubbell FA, et al. Self-sampling for human papillomavirus in a community setting: feasibility in Hispanic women. Cancer Epidemiol Biomarkers Prev 2008; 17(8): 2163-8.
29. Bais AG, van Kemenade FJ, Berkhof J, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007; 120: 1505-10.
30. Gök M, Heideman DAM, Kemenade FJ, et al. HPV testing on elfcollected cervico-vaginal lavage specimens is an effective screening method for non-attendees of cervical Screening: results from the PROHTECT cohort study. BMJ 2010; 340: c1040.